IDDF2021-ABS-0079 Switching from tenofovir disoproxil fumarate (TDF) and/or other oral antivirals (O...
IDDF2021-ABS-0079 Switching from tenofovir disoproxil fumarate (TDF) and/or other oral antivirals (OAVS) to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with hepatic impairment: final 2-year efficacy and safety results from a phase 2
About this item
Full title
Author / Creator
Lim, Young-Suk , Lin, Chun-Yen , Heo, Jeong , Bae, Ho , Chuang, Wan-Long , Yin Owen Tsang, Tak , Fournier, Claire , Hui, Aric Josun , Trinh, Huy , Yee Kwan Chan, Carol , Tan, Susanna K , Zhao, Yang , Flaherty, John F , Suri, Vithika , Gaggar, Anuj , Brainard, Dianna M , Ryder, Stephen and Janssen, Harry LA
Publisher
London: BMJ Publishing Group LTD
Journal title
Language
English
Formats
Publication information
Publisher
London: BMJ Publishing Group LTD
Subjects
More information
Scope and Contents
Contents
BackgroundWe have previously shown that in hepatically impaired CHB patients, switching to TAF from TDF and/or other OAVs maintains high rates of viral suppression with stable bone and renal safety parameters through 48 weeks. Here we present our final 2-year (Week 96) results.MethodsIn this Phase 2 study (NCT03180619), virally suppressed CHB patie...
Alternative Titles
Full title
IDDF2021-ABS-0079 Switching from tenofovir disoproxil fumarate (TDF) and/or other oral antivirals (OAVS) to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with hepatic impairment: final 2-year efficacy and safety results from a phase 2
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2568457768
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2568457768
Other Identifiers
ISSN
0017-5749
E-ISSN
1468-3288
DOI
10.1136/gutjnl-2021-IDDF.81
